Immunotherapy is a powerful technique where immune cells are modified to improve cytotoxicity against cancerous cells to treat cancers that do not respond to surgery, chemotherapy, or radiotherapy. Expressing chimeric antigen receptor (CAR) in immune cells, typically T lymphocytes, is a practical modification that drives an immune response against cancerous tissue. CAR-T efficacy is suboptimal in solid tumors due to the tumor microenvironment (TME) that limits T lymphocyte cytotoxicity. In this study, we demonstrate that neutrophils differentiated from human pluripotent stem cells modified with AAVS1-inserted CAR constructs showed a robust cytotoxic effect against prostate-specific membrane antigen (PSMA) expressing LNCaP cells as a model for prostate cancer in vitro . Our results suggest that engineered CAR can significantly enhance the neutrophil anti-tumor effect, providing a new avenue in treating prostate cancers.
Keyphrases
- pluripotent stem cells
- prostate cancer
- induced apoptosis
- radical prostatectomy
- immune response
- cell cycle arrest
- endothelial cells
- minimally invasive
- endoplasmic reticulum stress
- locally advanced
- benign prostatic hyperplasia
- oxidative stress
- peripheral blood
- coronary artery disease
- inflammatory response
- cell death
- computed tomography
- pet ct
- toll like receptor
- percutaneous coronary intervention
- cell proliferation
- pet imaging